StreetInsider.com News Articles

Incannex begins screening for sleep apnea drug study IHL-42X

Thu, 23 Jul 2026 08:00:16 -0400

Incannex Healthcare Inc. (Nasdaq: IXHL) announced that participant screening has begun in its DReAMzz Phase 2 dose confirmation study evaluating IHL-42X, a drug candidate for the treatment of obstructive sleep apnea (OSA).

According to a press release from the Melbourne- and New York-based clinical-stage biopharmaceutical company, the first clinical trial sites have received approval to screen potential participants. Additional sites are expected to begin screening as they receive the necessary regulatory approvals.

The DReAMzz study is a randomized, crossover Phase 2 trial designed to optimize the dosing profile of IHL-42X across both objective sleep metrics and patient-reported outcomes. The company states the

Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea

Thu, 23 Jul 2026 08:00:00 -0400

First clinical sites approved and actively screening potential participants
Represents another major milestone in the advancement of IHL-42X towards Phase III development
IHL-42X has received FDA Fast Track designation, highlighting its potential to address the significant unmet medical need in obstructive sleep apnea and supporting a potentially expedited regulatory pathway
Study designed to optimize both objective sleep metrics and patient-reported outcomes to support regulatory approval and commercial differentiation
Builds upon previously announced positive Phase 2 data demonstrating up to 83% reduction in AHI and significant improvements across multiple patient-reported outcome measures
Obstructive

Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea

Thu, 23 Jul 2026 08:00:00 -0400

First clinical sites approved and actively screening potential participants
Represents another major milestone in the advancement of IHL-42X towards Phase III development
IHL-42X has received FDA Fast Track designation, highlighting its potential to address the significant unmet medical need in obstructive sleep apnea and supporting a potentially expedited regulatory pathway
Study designed to optimize both objective sleep metrics and patient-reported outcomes to support regulatory approval and commercial differentiation
Builds upon previously announced positive Phase 2 data demonstrating up to 83% reduction in AHI and significant improvements across multiple patient-reported outcome measures
Obstructive

Form 8-K Incannex Healthcare Inc. For: Jul 23

Thu, 23 Jul 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260723/26804624.html

Form 8-K Incannex Healthcare Inc. For: Jul 23

Thu, 23 Jul 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260723/26804624.html

Incannex gets U.S. patent for sleep apnea drug IHL-42X through 2040

Thu, 25 Jun 2026 08:00:22 -0400

Incannex Healthcare Inc. (NASDAQ: IXHL) has received a U.S. patent from the United States Patent and Trademark Office for its IHL-42X drug candidate, an oral combination therapy in development for obstructive sleep apnea (OSA).

The patent, titled "Compositions and Methods of Treatment for Obstructive Sleep Apnea," covers the proprietary IHL-42X composition and associated therapeutic methods. It carries a baseline expiry date of July 9, 2040. The company said it is exploring eligibility for a patent term extension following potential FDA approval.

Incannex said it is also reviewing data from the IHL-42X development program with the aim of filing additional patent applications.

IHL-42X holds

Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea

Thu, 25 Jun 2026 08:00:00 -0400

MELBOURNE, Australia and NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company developing innovative combination therapies for high-impact indications, today announced that the United States Patent and Trademark Office (USPTO) has granted a key patent titled “Compositions and Methods of Treatment for Obstructive Sleep Apnea.”

The granted patent includes claims directed to the proprietary IHL-42X composition and its associated therapeutic methods for the treatment of Obstructive Sleep Apnea (OSA). The patent is expected to have a baseline expiry date of 9 July 2040 and the

Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea

Thu, 25 Jun 2026 08:00:00 -0400

Form 8-K Incannex Healthcare Inc. For: Jun 25

Thu, 25 Jun 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260625/26688282.html

Form 8-K Incannex Healthcare Inc. For: Jun 25

Thu, 25 Jun 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260625/26688282.html

Incannex receives A$6 million R&D tax refund from Australia

Wed, 10 Jun 2026 08:02:05 -0400

Incannex Healthcare Inc. (NASDAQ: IXHL) received A$6,039,162.43 under the Australian Government's Research and Development Tax Incentive Program, according to a company statement.

The clinical-stage biopharmaceutical company expects to receive an additional A$5.1 million in future R&D tax incentive proceeds in 2026. The combined proceeds represent more than A$11.1 million in non-dilutive capital.

The Australian Government's Research and Development Tax Incentive Program provides eligible companies with cash refunds for qualifying research and development activities conducted in Australia. The proceeds are non-dilutive, allowing companies to recover research and development expenditure without issuing additional shares or taking on debt.

"The receipt of more than A$6 million

Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility